


HEALTHCARE

Generic Pharmaceutical Outlook 1998-2008

By James Moore

 [Table of Contents](#)

James Moore

James Moore is a consultant in Datamonitor's Healthcare Practice Area. He has degrees in European Finance and Accounting from Leeds University and Normandy Business School. Since joining Datamonitor, James has worked extensively on corporate strategy and disease-specific issues within the pharmaceutical and healthcare industries.

Copyright © 1998 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Printed and bound in Great Britain by MBA Group Limited, MBA House, Garman Road, London N17 0HW. www.mba-group.com

Table of Contents

The Generic Pharmaceuticals Outlook 1998-2008 1

Executive summary 7

Introduction to generics	7
Generic penetration in key therapeutic categories	8
Generic penetration in key national markets	9
Key generics legislation	10
The response of the branded sector to generic competition	11
Selected company profiles and performance analysis	12
The future of the generics industry	13

Chapter 1 Introduction to generics 15

Definitions	16
The imprecise definition of generics	16
The pharmaceutical lifecycle	16
Advantages of generics	21
Market overview	22
The global generics market	22
Major generics markets	24
Generic market drivers	25
Key players in generics	27
Innovation versus imitation	27
Comparison between generics and branded manufacturers	28
Consolidation within the generics industry	31

Chapter 2 Generic penetration in key therapeutic categories 33

Overview of therapeutic categories	35
Generic penetration	36
National market trends	38
The market for generic cardiovascular drugs	39
Penetration of cardiovascular generics in national markets	43
Case study - Merck's Mevacor	44

The market for generic CNS drugs	50
The global CNS market	51
The CNS generics market	53
Generic penetration in CNS market segments	56
Developing CNS generics market segments	58
The market for generic cancer drugs	61
The global cancer market	61
The cancer generics market	62
Future development of the cancer generics market	68

Chapter 3 Generic penetration in key national markets 73

The Canadian generics market	74
Overview of the Canadian healthcare system	74
Market drivers	74
Current status of the market	78
Recent events	79
The French generics market	81
Overview of the French healthcare system	81
Market drivers	82
Current status of the market	83
Recent events	84
The German generics market	85
Overview of the German healthcare system	85
Market drivers	86
Current status of the market	87
Recent events	88
The UK generics market	90
Overview of the UK healthcare system	90
Market drivers	90
Current status of the market	92
Recent events	93
The US generics market	94
Overview of the US healthcare system	94
Market drivers	95
Current status of the market	97
Recent events	98
Key differences between major markets	99
Generic substitution	100
Managed care	100
Purchaser power	101
Influence of market factors on the success of generics	101
Global trends	101
National trends	104

Chapter 4 Key generics legislation 109

Influence of the EU on European generics markets	110
Legislation	110
Key international patent agreements	117
Gatt	117
Trips	118
The Paris Convention	120
The Patent Co-operation Treaty	121
Prolonging patent protection: Gatt and the Waxman-Hatch act	123
Gatt and Trips	123
The Waxman-Hatch Act	124
Winners and losers in the Gatt extension	125
Case study - Glaxo Wellcome and Zantac	126

Chapter 5 The response of the branded sector to generic competition 129

Tactics for responding to generic competition	130
New formulations	132
Overview	132
Case study – Pfizer’s Procardia XL	134
New indications	137
Case study: Abbott’s Depakote	137
Consolidation	139
R _x -to-OTC switching	140
Case study - SmithKline Beecham and Tagamet	144
Ethical manufacturers move into generics	148
Case study - Bristol-Myers Squibb’s Capoten	150
Multiple generics defence strategies	152
Case study - Astra’s Losec/Prilosec	152
The viability of generics defence strategies?	157

Chapter 6 Selected company profiles and performance analysis 161

Barr Laboratories	162
Mylan Laboratories	164
Teva Pharmaceuticals	166
Watson Pharmaceuticals	171
Comparison of performance ratios of generics and branded companies	174
Company selection	175
Return on investment ratios	177

Return on total assets	179
Net profit margin versus ROTA	181
Return on equity and debt to equity funding ratios	182
What determines the level of equity investment?	184

Chapter 7 The future of the generics industry 186

The generics marketplace post-2000	187
Patent expirations	187
Other market drivers	190
Generics strategies for the 21st century	192

Chapter 8 Appendix 196

Primary research methodology	196
Financial glossary and data table	197
Index	198

List of Figures

Figure 1.1:	The pharmaceutical lifecycle	17
Figure 1.2:	Impact of the launch of multiple commodity generics on gross margin	19
Figure 1.3:	Breakdown of the global generics market by value, 1997	23
Figure 1.4:	Overview of the generics market	25
Figure 1.5:	Market penetration and estimated growth of generics, 1995–2005	27
Figure 1.6:	Basis of competition between branded and generics companies	30
Figure 2.7:	Segmentation of the global pharmaceutical market by therapeutic category according to value, 1997	35
Figure 2.8:	Segmentation of the global pharmaceutical market by therapeutic category, 1998	37
Figure 2.9:	Perceived relative susceptibility to generic competition of therapeutic categories within key national markets, 1998	38
Figure 2.10:	Relative perceived levels of generic competition in cardiovascular market segments, 1998	40
Figure 2.11:	Distribution of cardiovascular generic products marketed in the UK by mechanism, 1997	41
Figure 2.12:	Significance of cardiovascular generics to the US pharmaceutical market by value, 1997	44
Figure 2.13:	US patent term extensions for Merck's Mevacor, 1998	45
Figure 2.14:	Significance of cardiovascular generics to the Canadian pharmaceutical market by value, 1997	47
Figure 2.15:	Significance of cardiovascular generics to the German pharmaceutical market by value, 1997	48
Figure 2.16:	Significance of cardiovascular generics to the UK pharmaceutical market by value, 1997	49

Figure 2.17:	Significance of cardiovascular generics to the French pharmaceutical market by value, 1997	50
Figure 2.18:	Breakdown of the global CNS market, 1997	52
Figure 2.19:	The CNS Generics Market, 1998	53
Figure 2.20:	Susceptibility of CNS sectors to generic penetration, 1998	57
Figure 2.21:	Breakdown of the global cancer market, 1997	62
Figure 2.22:	Relative market sizes of generic and multisource cancer drugs in five key markets, 1997	65
Figure 2.23:	Forecast market value of the US, German and UK cancer generics markets, 1997–2010	70
Figure 2.24:	Forecast generic share of the US, German and UK cancer markets, 1997–2010	71
Figure 3.25:	Canadian generic pharmaceutical approval process, 1998	77
Figure 3.26:	Global influence of market factors on the success of generic drugs, 1998	102
Figure 3.27:	National trends in influential market factors on the success of generics, 1998	105
Figure 4.28:	Impact of SPCs on drug patent reform	111
Figure 4.29:	Sales of Glaxo Wellcome's Zantac, 1991–97	128
Figure 5.30:	Sales of Pfizer's Procardia and Procardia XL, 1990–97	136
Figure 5.31:	Sales of Abbott's Depakote, 1990–97	139
Figure 5.32:	Declining sales of SmithKline Beecham's ethical Tagamet, 1990–1997	145
Figure 6.33:	Average net and operating profit margins, 1997	176
Figure 6.34:	Return on investment ratios, 1997	178
Figure 6.35:	Breakdown of ROTA by sales margin and asset turn, 1997	180
Figure 6.36:	Individual companies positioned by net profit margin and ROTA, 1997	182
Figure 6.37:	ROE versus proportion of equity funding, 1997	183
Figure 6.38:	ROE versus proportion of equity funding for sample generics companies, 1997	184
Figure 6.39:	Spread of equity funding, 1997	185
Figure 7.40:	Value of branded drugs coming off-patent in the US, 1998–2008	189
Figure 7.41:	Current company revenue levels exposed to patent expiration, 1998–2003	190

List of Tables

Table 1.1:	Generic share of pharmaceutical markets by value	24
Table 1.2:	Net sales and profitability of leading generics companies, 1997	28
Table 2.3:	Segmentation of the global pharmaceutical market by therapeutic area according to value, 1997	36
Table 2.4:	Quantities of generics vs. branded cardiovascular products marketed in the UK, 1997	42
Table 2.5:	Cardiovascular generic penetration into the US market, 1997	43
Table 2.6:	Cardiovascular generic penetration into the Canadian market, 1997	46
Table 2.7:	Cardiovascular generic penetration into the German market, 1997	47
Table 2.8:	Cardiovascular generic penetration into the UK market, 1997	48
Table 2.9:	Cardiovascular generic penetration into the French market, 1997	49
Table 2.10:	Breakdown of the global CNS market, 1997	51
Table 2.11:	Breakdown of the global cancer market, 1996–997	62
Table 2.12:	Summary of key differences between the five cancer generics markets examined	66
Table 4.13:	European patent fees, 1998	110
Table 4.14:	Benefits to leading manufacturers from-extended patent lives	125
Table 4.15:	Sales of Glaxo Wellcome's Zantac, 1991–1997	127

Table 5.16:	Sales of Pfizer's Procardia and Procardia XL, 1990–1997	135
Table 5.17:	Sales of Abbott's Depakote, 1990–1997	138
Table 5.18:	Declining sales of SmithKline Beecham's Tagamet, 1990–1997	145
Table 5.19:	Generic subsidiaries of multinational drug companies, 1998	149
Table 5.20:	Sales of Losec and Prilosec, 1995–1997	152
Table 5.21:	Selected patents and other legal forms of protection for Losec/Prilosec, 1998	153
Table 6.22:	Barr Laboratories financial overview, 1993–1997	162
Table 6.23:	Mylan Laboratories financial overview, 1994–1998	164
Table 6.24:	Teva Pharmaceuticals financial overview, 1993–1997	167
Table 6.25:	Watson Pharmaceuticals financial overview, 1996–1997	172
Table 6.26:	Watson Pharmaceuticals' subsidiaries, 1998	173
Table 6.27:	Selected industries and sample companies	175
Table 6.28:	Average sector-sample return on investment ratios, 1997	178
Table 7.29:	Value of branded drugs losing coming off-patent in the US, 1998–2008	188
Table 8.30:	Pharmaceutical company data table	197